Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer
2022
Juen, Ludovic | Baltus, Christine | Gély, Camille | Kervarrec, Thibault | Feuillâtre, Ofelia | Desgranges, Audrey | Viaud-Massuard, Marie-Claude | Martin, Camille | McSAF | Infectiologie et Santé Publique | Université de Tours -Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement | GICC EA , IMT | Groupe innovation et ciblage cellulaire , EA | Université de Tours -Université de Tours | This work was supported by McSAF, the BPI , and the Conseil Regional de la region Centre-Val de Loire
International audience
Show more [+] Less [-]English. With three clinically approved antibody-drug conjugates targeting HER2, this target is clearly identified to be of interest in oncology. Moreover, the advent of new bioconjugation technologies producing site-specific homogenous conjugates led to the opportunity of developing new medicines linking antibodies and payloads. Here, a new relevant HER2-targeting ADC was obtained by the conjugation of monomethyl auristatin E onto trastuzumab using McSAF Inside bioconjugation technology. The antibody-drug conjugate formed presented an average drug-to-antibody ratio of 4 with a high homogeneity and an excellent stability especially when incubated with human serum albumin or in human plasma. Moreover, it demonstrated a strong efficacy in an HER2 xenograft tumor model in mice, superior to the clinically approved antibody-drug conjugate ado-trastuzumab emtansine, with a complete tumor regression observed both macroscopically and microscopically demonstrating its therapeutic potential.
Show more [+] Less [-]Bibliographic information
This bibliographic record has been provided by National Institute for Agricultural Research